Skip to main content

Peer Review reports

From: A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer

Original Submission
26 Jan 2021 Submitted Original manuscript
30 Jun 2021 Author responded Author comments - wanjun yu
Resubmission - Version 2
30 Jun 2021 Submitted Manuscript version 2
5 Jul 2021 Editorially accepted
31 Jul 2021 Article published 10.1186/s12885-021-08590-1

You can find further information about peer review here.

Back to article page